School of Medicine


Showing 121-140 of 165 Results

  • Sonia Rios-Ventura

    Sonia Rios-Ventura

    Family Health Navigator, Medicine - Med/Oncology

    BioSonia Rios-Ventura is a clinical research coordinator associate for the Stanford School of Medicine, department of Cancer Genetics and Genomics. She received her B.A. in anthropology and intensive sociology from the University of California Santa Cruz.

    She is also the family health navigator for the Genetic Information and Family Testing (GIFT) Study. GIFT's mission is to help families beat cancer. It aims to save lives through education and communication about cancer risk and prevention in families. When someone learns they have a genetic mutation that increases their risk for cancer, it means their family members might also be at risk. For too long, the difficult job of talking about family cancer risk has fallen to the cancer patients alone. GIFT is here to make it easier for people to share this important information and give family members an easy way to get genetic testing to learn about their personal cancer risk. GIFT is an online program developed by cancer patients, family members, and doctors that offers a new way to, 1. Share life-saving information about family cancer risk and ways to lower that risk, 2.Connect interested family members to easy, at-home genetic testing.

  • Rajat Rohatgi

    Rajat Rohatgi

    Professor of Biochemistry and of Medicine (Oncology)

    Current Research and Scholarly Intereststhe overall goal of my laboratory is to uncover new regulatory mechanisms in signaling systems, to understand how these mechanisms are damaged in disease states, and to devise new strategies to repair their function.

  • Mohana Roy, MD

    Mohana Roy, MD

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Roy is a medical oncologist and a clinical assistant professor in the Stanford University School of Medicine Department of Medicine, Division of Medical Oncology. She has expertise in Lung and Thoracic cancers, but with a broad clinical interest in hematology and oncology.

    Dr. Roy became an oncologist because of her passion for patient care. She is committed to being a clinician and is focused on improving the patient experience -- from the moment a patient checks in, to how information about their care is conveyed, and how the complex process of getting cancer care can be made a bit more seamless.

    Her research interests include access to clinical trials, quality improvement and improving care delivery. In that effort, she has published on work regarding patient reported outcomes (PROs) and their use to help clinical quality efforts- including in the context of a clinical trial with an electronic PRO portal, through distress screening with the Stanford Medicine Cancer Center, and in improving access to such screening and care for patient with limited English proficiency. She is the recipient of both a clinical innovation award through Stanford and an American Society of Clinical Oncology (ASCO) Merit award.

    She is the Associate Medical Director for Quality at Stanford Cancer Center from 2022.

    Dr. Roy received her medical degree from Albert Einstein College of Medicine, and then completed residency training at Beth Israel Deaconess Medical Center. She then completed fellowship training in Hematology and Oncology at Stanford. She was chief fellow for her graduating year during fellowship as well.

  • Anuja Anand Sathe

    Anuja Anand Sathe

    Instructor, Medicine - Oncology

    Current Research and Scholarly InterestsI am interested in understanding the determinants of therapeutic resistance in cancer. I investigate the composition of the tumor microenvironment and adaptive responses to therapy using single-cell and spatial approaches.

  • Lidia Schapira

    Lidia Schapira

    Professor of Medicine (Oncology)

    BioDr. Schapira is a medical oncologist with clinical expertise in the treatment of breast cancer. As the inaugural Director of Stanford's Cancer Survivorship Program, she has developed a thriving research and clinical program focused on optimizing health outcomes for people living with and beyond cancer. Dr. Schapira is interested in training future generations of physician-scientists as well as the broader community of practicing physicians through the design of innovative educational programs. Dr. Schapira's advocacy for people with cancer led to her appointment as Editor-in-Chief of the American Society of Clinical Oncology's website for the public,Cancer.Net, a position she held from 2015 until-2021. She served on the Board of Directors of the American Psychosocial Oncology Society and as Chair of the Psychosocial Interest Group of the Multinational Society for Supportive Care in Cancer. Dr. Schapira is particularily committed to reducing inequities in cancer outcomes and improve access to cancer care and cancer clinical trials. Dr. Schapira has published numerous manuscripts, lectures both nationally and internationally on issues of cancer survivorship and served as Associate Editor of the narrative section, Art of Oncology, for the Journal of Clinical Oncology from 2013 until 2023.

  • Joseph Schroers-Martin

    Joseph Schroers-Martin

    Assistant Professor of Medicine (Oncology)

    Current Research and Scholarly InterestsMedical heme/onc focused on molecular cancer diagnostics and novel biomarkers.

  • Arpeet Tarun Shah, MD

    Arpeet Tarun Shah, MD

    Affiliate, Medicine - Med/Oncology

    BioDr. Shah practices hematology and oncology. He has fellowship training in both specialties and is board-certified in hematology, oncology, and internal medicine.

    Dr. Shah is passionate about delivering patient-centered care. He aims to balance evidence-based treatments with each patient’s individual preferences. His goal is to maximize both clinical outcomes and quality of life.

    He feels privileged to have the opportunity to work so closely with patients and their families. Together, they can find and pursue what is important to them throughout their cancer journey.

    In addition to providing clinical care, Dr. Shah has conducted research. His research interests include molecular testing and immunotherapy outcomes in patients with non-small cell lung cancer (NSCLC).

    Dr. Shah has co-authored articles on treatment for NSCLC and other topics in publications such as Clinical Lung Cancer and Journal of Oncology Practice.

    He has made presentations to his peers at the American Society of Clinical Oncology–Society for the Immunotherapy of Cancer (ASCO-SITC) annual meeting and other conferences. He also has helped develop the curriculum and taught students in hematology, oncology, internal medicine, and neurobiology. In his hematology/oncology fellowship at Stanford, he was a senior teaching fellow.

    Dr. Shah was also a Johnson & Johnson Global Health Scholar, serving for two months as a visiting resident scholar in Kampala, Uganda.

    When not working, he enjoys reading, trying new recipes, and exploring parks with his family.

  • Sumit Shah

    Sumit Shah

    Clinical Associate Professor, Medicine - Oncology
    Clinical Associate Professor (By courtesy), Urology

    BioDr. Sumit Shah specializes in the management of advanced urologic malignancies such as prostate, kidney, bladder, and testicular cancers. He also serves as an investigator on numerous clinical trials, with a focus on novel immunotherapy agents. His academic interests also include digital health technologies and novel healthcare delivery services, both in the domestic and international setting. Dr. Shah graduated with distinction in biomedical engineering from Duke University, received his medical doctorate from Stanford University, and Masters in Public Health from Harvard University. He completed his internal medicine residency at the University of California, San Francisco (UCSF) where he stayed on faculty for one year before returning to Stanford for his fellowship training in medical oncology, where he now serves on the faculty.

  • Shagufta Shaheen

    Shagufta Shaheen

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Shaheen specializes in the gastrointestinal malignancies and she has expertise in treating neuroendocrine tumors (NETs). Following her fellowship in Hematology and Oncology, Dr Shaheen completed an advanced fellowship in Neuroendocrine tumors from Stanford University. The NET advanced fellowship is first of its kind in United State started under the leadership of Dr Pamela Kunz who is the founding Director of the Stanford Neuroendocrine Tumor Program established in 2015. After completing her advanced fellowship, Dr Shaheen joined Stanford Oncology division as Clinical Assistant Professor. Dr Shaheen is involved in further developing the neuroendocrine oncology program at Stanford which serves as a centre of excellence in the treatment of neuroendocrine tumors. Dr Shaheen is actively involved in clinical research and clinical trials. Dr Shaheen is also involved in taking care of patients admitted to the oncology service as well as resident and fellow teaching.

  • Anjali Sibley MD, MPH

    Anjali Sibley MD, MPH

    Clinical Associate Professor, Medicine - Oncology

    BioDr. Sibley is a Clinical Associate Professor of Medicine (Oncology) at Stanford School of Medicine. She is the Director of the Stanford Medicine Cancer Center in Emeryville and is a board-certified, fellowship-trained hematologist and medical oncologist.

    Her clinical interests include treating solid tumor cancers, lung cancers, blood cancers and benign blood conditions. She is interested in cancer prevention and reducing disparities in hematologic/oncologic care among underserved populations, and successful cancer survivorship programs.

    In addition to responsibilities related to patient care and overseeing the Cancer Center in Emeryville, Dr. Sibley has developed and is leading an innovative cancer survivorship clinic, including an exercise initiative. She also is passionate about advancing clinical trial enrollment for medically underserved populations and she serves on the Cancer Network’s East Bay Health Equity Committee leading lung cancer screening efforts in the East Bay. She is also working on a Stanford Cancer Institute-funded study examining psychosocial factors and cardiac health in Black cancer patients in the East Bay.

    She believes that providing patient care is a true privilege. Dr. Sibley utilizes a patient-centered practice approach that addresses multiple aspects of a patient’s well-being. Her research interests have included chemoprevention of breast cancer and the development of magnetic resonance imaging technology in breast cancer detection and mapping. She has also led community-based efforts to implement low-dose computed tomography (LDCT) as a screening tool for cancer.

    Dr. Sibley’s publications include articles on breast cancer prevention, breast magnetic resonance imaging, and other topics. Her work has appeared in American Journal of Hematology, JAMA, the Breast Journal, Internal Medicine News, and elsewhere. Dr. Sibley was invited to deliver a peer-reviewed presentation on community-based cancer screening and preventive education to the Global Health Council. Dr. Sibley is on the board of directors of the Cancer Support Community SF Bay Area. She has also served as a clinic physician for the Native American Health Center of Oakland, on the Committee on Health Equity of the American Public Health Association, and as chair and vice chair of the Cancer Forum Caucus of the American Public Health Association. She is a member of the American Society of Clinical Oncology, American Society of Preventive Oncology, and American Society of Hematology. She has provided volunteer services to the Global Health Council and to the Cancer Patients Aid Association, for whom she conducted a patient screening and education program in Mumbai, India.

  • Branimir I. Sikic, M. D.

    Branimir I. Sikic, M. D.

    Professor of Medicine (Oncology), Emeritus

    Current Research and Scholarly InterestsResearch Interests: cancer pharmacology, mechanisms of resistance to anticancer drugs, regulation and function of MDR1 and tubulin genes, CD47 as a target for activation of anticancer macrophases, Phase I trials of new drugs, gene expression profiling of cancers